Research Shows Benefits of Eliquis Over Warfarin For Atrial Fibrillation Patients

Video

While warfarin has long been a common treatment option for patients with atrial fibrillation new medications are coming to the market which provide different benefits than the original option.

While warfarin has long been a common treatment option for patients with atrial fibrillation new medications are coming to the market which provide different benefits than the original option.

Jack Lawrence, MD, Vice President, Cardiovascular Specialty Development and Development Lead for Apixaban at Bristol-Myers Squibb, and Christoph Koenen, Vice President, Cardiovascular, at Bristol-Myers discussed the development of the treatment option during the annual American Heart Association Scientific Sessions in Orlando.

With new treatment medications available, particularly when it comes to anticoagulants there is good news for patient care. That good news is expected to continue into the future.

Related Videos
A panel of 5 cardiovascular experts
Video 5 - "Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice" - Featuring 1 KOL
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Video 4 - "Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes "
Video 3 - "Aligning With 2023 ESC Guidelines in oHCM Treatment"
Robert Rosenson, MD | Credit: Cura Foundation
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Robert Rosenson, MD | Credit: Cura Foundation
© 2024 MJH Life Sciences

All rights reserved.